Browsed by
Category: Science

What It Will Be Like to Be an 85-Year-Old in the 2070s – Article by Scott Emptage

What It Will Be Like to Be an 85-Year-Old in the 2070s – Article by Scott Emptage

Scott Emptage


I will be 85 sometime in the early 2070s. It seems like a mirage, an impossible thing, but the future eventually arrives regardless of whatever you or I might think about it. We all have a vision of what it is to be 85 today, informed by our interactions with elder family members, if nothing else. People at that age are greatly impacted by aging. They falter, their minds are often slowed. They are physically weak, in need of aid. Perhaps that is why we find it hard to put ourselves into that position; it isn’t a pleasant topic to think about. Four decades out into the future may as well be a science-fiction novel, a faraway land, a tale told to children, for all the influence it has on our present considerations. There is no weight to it.

When I am 85, there will have been next to no senescent cells in my body for going on thirty years. I bear only a small fraction of the inflammatory burden of older people of past generations. I paid for the products of companies descended from Oisin Biotechnologies and Unity Biotechnology, every few years wiping away the accumulation of senescent cells, each new approach more effective than the last. Eventually, I took one of the permanent gene therapy options, made possible by biochemical discrimination between short-term beneficial senescence and long-term harmful senescence, and then there was little need for ongoing treatments. Artificial DNA machinery floats in every cell, a backup for the normal mechanisms of apoptosis, triggered by lingering senescence.

When I am 85, the senolytic DNA machinery will be far from the only addition to my cells. I underwent a half dozen gene therapies over the years. I picked the most useful of the many more that were available, starting once the price fell into the affordable-but-painful range, after the initial frenzy of high-cost treatments subsided into business as usual. My cholesterol transport system is enhanced to attack atherosclerotic lesions, my muscle maintenance and neurogenesis operate at levels far above what was once a normal range for my age, and my mitochondria are both enhanced in operation and well-protected against damage by additional copies of mitochondrial genes backed up elsewhere in the cell. Some of these additions were rendered moot by later advances in medicine, but they get the job done.

When I am 85, my thymus will be as active as that of a 10-year-old child. Gene and cell therapies were applied over the past few decades, and as a result my immune system is well-gardened, in good shape. A combination of replacement hematopoietic stem cells, applied once a decade, the enhanced thymus, and periodic targeted destruction of problem immune cells keeps at bay most of the age-related decline in immune function, most of the growth in inflammation. The downside is that age-related autoimmunity has now become a whole lot more complex when it does occur, but even that can be dealt with by destroying and recreating the immune system. By the 2030s this was a day-long procedure with little accompanying risk, and the price fell thereafter.

When I am 85, atherosclerosis will be curable, preventable, and reversible, and that will have been the case for a few decades. There are five or six different viable approaches in the marketplace, all of which basically work. I used several of their predecessors back in the day, as well. Most people in the wealthier parts of the world have arteries nearly free from the buildup of fat and calcification. Cardiovascular disease with age now has a very different character, focused more failure of tissue maintenance and muscle strength and the remaining small portions of hypertension that are still problematic for some individuals. But that too can be effectively postponed through a variety of regenerative therapies.

When I am 85, there will be an insignificant level of cross-linking in most of my tissues, as was the case since my early 60s. My skin has the old-young look of someone who went a fair way down the path before being rescued. Not that I care much about that – I’m much more interested in the state of my blood vessels, the degree to which they are stiff and dysfunctional. That is why removal of cross-links is valuable. That is the reason to keep on taking the yearly treatments of cross-link breakers, or undergo one of the permanent gene therapies to have your cells produce protective enzymes as needed.

When I am 85, I will have a three-decade patchwork history of treatments to partially clear this form of amyloid or that component of lipofuscin. I will not suffer Alzheimer’s disease. I will not suffer any of the common forms of amyloidosis. They are controlled. There is such a breadth of molecular waste, however: while the important ones are addressed, plenty more remain. This is one of the continuing serious impacts to the health of older individuals, and a highly active area of research and development.

When I am 85, I will be the experienced veteran of several potentially serious incidences of cancer, all of which were identified early and eradicated by a targeted therapy that produced minimal side-effects. The therapies evolve rapidly over the years: a bewildering range of hyper-efficient immunotherapies, as well as treatments that sabotage telomere lengthening or other commonalities shared by all cancer cells. They were outpatient procedures, simple and quick, with a few follow-up visits, so routine that they obscured the point that I would be dead several times over without them. The individual rejuvenation technologies I availed myself of over the years were narrowly focused, not perfect, and not available as early as I would have liked. Cancer is an inevitable side-effect of decades of a mix of greater tissue maintenance and unrepaired damage.

Do we know today what the state of health of a well-kept 85-year-old will be in the 2050s? No. It is next to impossible to say how the differences noted above will perform in the real world. They are all on the near horizon, however. The major causes of age-related death today will be largely controlled and cured in the 2050s, at least for those in wealthier regions. If you are in your 40s today, and fortunate enough to live in one of those wealthier region, then it is a given that you will not die from Alzheimer’s disease. You will not suffer from other common age-related amyloidosis conditions. Atherosclerosis will be reliably controlled before it might kill you. Inflammatory conditions of aging will be a shadow of what they once were, because of senolytic therapies presently under development. Your immune system will be restored and bolstered. The stem cells in at least your bone marrow and muscles will be periodically augmented. The cross-links that cause stiffening of tissues will be removed. Scores of other issues in aging process, both large and small, will have useful solutions available in the broader medical marketplace. We will all live longer and in better health as a result, but no-one will be able to say for just how long until this all is tried.

Scott Emptage is an anti-aging activist in the United Kingdom. 

Third Enlightenment Salon – Gennady Stolyarov II, Bill Andrews, Bobby Ridge, and Mihoko Sekido Discuss Science-Based Advocacy of Transhumanism and Healthy Living

Third Enlightenment Salon – Gennady Stolyarov II, Bill Andrews, Bobby Ridge, and Mihoko Sekido Discuss Science-Based Advocacy of Transhumanism and Healthy Living

Gennady Stolyarov II
Bill Andrews
Bobby Ridge
Mihoko Sekido


The Third Enlightenment Salon, hosted by Gennady Stolyarov II on May 27, 2018, featured excellent conversations on the rise in public awareness of transhumanism and life extension and what can be done to further increase support for life-extending medical research. Dr. Bill Andrews, Bobby Ridge (a.k.a. Robert Ridge), and Mihoko Sekido shared insights on medical science, promotion of health, and methods of communicating the forthcoming convergence of advances in a wide array of technological fields. Importantly, we addressed how anyone can get involved in the transhumanist movement and improve public acceptance of the emerging technological future.

The following were some interesting areas of discussion:

– The new Telomere Coin, which will help fund Dr. Andrews’s research efforts – http://defytime.group/
– Bobby Ridge’s forthcoming new video channel – Science-Based Species
– Aspects of online videos that help increase their reach
– Factors that contribute to longer lifespans among Okinawans
– Motivators for leading a healthier lifestyle and its relation to the recognition of the possibility of indefinite life extension in our lifetimes
– Some potential health effects of metformin and the importance of the ongoing TAME clinical trials
– What anyone can do to promote life extension and other emerging technological fields – including joining the U.S. Transhumanist Party for free on this page.

This video also contains some excerpts from the remaining conversations at the Third Enlightenment Salon, including discussions of science-based medicine, promotion of transhumanism, autonomous vehicles, and responses to the prospect of longevity escape velocity.

Along with the recorded segment, there was much discussion about future directions of transhumanist initiatives, reasonably healthy food in a refined atmosphere, and previews of excellent video compilations that will become publicly available later this year. Mr. Stolyarov looks forward to hosting more Enlightenment Salons to bring together individuals in various fields of expertise and enable them to synthesize their insights into ways of comprehensively improving the human condition.

Second Enlightenment Salon – G. Stolyarov II, Bill Andrews, Bobby Ridge, and Scott Jurgens Discuss the Convergence of Technological Advances

Second Enlightenment Salon – G. Stolyarov II, Bill Andrews, Bobby Ridge, and Scott Jurgens Discuss the Convergence of Technological Advances

Gennady Stolyarov II

Bill Andrews

Bobby Ridge

Scott Jurgens


U.S. Transhumanist Party Chairman Gennady Stolyarov II invited Dr. Bill Andrews (the U.S. Transhumanist Party’s Biotechnology Advisor), Bobby Ridge (the U.S. Transhumanist Party’s Secretary-Treasurer), and Scott Jurgens to his Second Enlightenment Salon, where they shared their thoughts on emerging life-extension research, advances in prosthetics and orthotics, philosophy of science, brain-computer interfaces, and how technologies from a variety of fields are converging to bring about a paradigm shift in the human condition – hopefully within the coming decades.

U.S. Transhumanist Party Discussion on Prosthetics, Neuroscience, and the Future of Human Potential

U.S. Transhumanist Party Discussion on Prosthetics, Neuroscience, and the Future of Human Potential

The New Renaissance Hat

G. Stolyarov II

Bobby Ridge

Scott Jurgens

September 18, 2017


References

– Hugh Herr – “The new bionics that let us run, climb, and dance” – TED – March 2014
– LimbForge – Enable Community Foundation
– Autodesk Fusion 360
– Thingiverse
– “Metal Gear Solid 5 Inspires an Amazing Prosthetic Arm” – Kendall Ashley – Nerdist – May 23, 2016

Learn more about the U.S. Transhumanist Party here.

Become a member of the U.S. Transhumanist Party for free, no matter where you reside. Fill out our Membership Application Form here.

Become a Foreign Ambassador for the U.S. Transhumanist Party. Apply here.

Panel – Artificial Intelligence & Robots: Economy of the Future or End of Free Markets? – Michael Shermer, Edward Hudgins, Zoltan Istvan, Gennady Stolyarov II, Eric Shuss

Panel – Artificial Intelligence & Robots: Economy of the Future or End of Free Markets? – Michael Shermer, Edward Hudgins, Zoltan Istvan, Gennady Stolyarov II, Eric Shuss

The New Renaissance Hat

G. Stolyarov II

Michael Shermer

Edward Hudgins

Zoltan Istvan

Eric Shuss

July 28, 2017


Gennady Stolyarov II, Chairman of the U.S. Transhumanist Party, participated in the panel discussion at FreedomFest in Las Vegas on July 21, 2017, entitled “AI & Robots: Economy of the Future or End of Free Markets?” The panelists presented a set of realistic, balanced analyses on the impact of artificial intelligence and automation.

***

For this event there was an outstanding speaker lineup, with moderator Michael Shermer, followed by Edward Hudgins, Peter Voss, Zoltan Istvan, Gennady Stolyarov II, and Eric Shuss.

***

The general focus of Mr. Stolyarov’s remarks was to dispel AI-oriented doomsaying and convey the likely survival of the capitalist economy for at least the forthcoming several decades – since narrow AI cannot automate away jobs requiring creative human judgment.

***

The video was recorded by filmmaker Ford Fischer and is reproduced with his permission.

Visit Ford Fischer’s News2Share channel here.

Visit the U.S. Transhumanist Party website here.

Join the U.S. Transhumanist Party for free by filling out our membership application form here.

Visit the U.S. Transhumanist Party Facebook page here.

Visit the U.S. Transhumanist Party Twitter page here.

U.S. Transhumanist Party Interview with Bobby Ridge

U.S. Transhumanist Party Interview with Bobby Ridge

The New Renaissance Hat
Gennady Stolyarov II and Bobby Ridge
July 8, 2017
******************************

 


Gennady Stolyarov II, Chairman of the United States Transhumanist Party, interviews Bobby Ridge, a researcher into transhumanist philosophy and the scientific method and the new Secretary-Treasurer of the United States and Nevada Transhumanist Parties.

Watch this conversation regarding the subjects of Mr. Ridge’s research, the scientific method, and transhumanism more generally.

Bobby Ridge has a Bachelor’s Degree in Biomedical Science from California State University of Sacramento (CSUS) and is striving to achieve his MD in Neurology. He only recently became a Transhumanist. He conducts research for CSUS’s Psychology Department and his own personal research on the epistemology and Scientiometrics of the Scientific Method. He also co-owns Togo’s in Citrus Heights, CA. Mr. Ridge considers transhumanism to describe the future of humanity taking its next steps in evolution, which are both puissant and daunting. With the exponential increase in information technology, Mr. Ridge considers it important for us to become a science-based species to prevent a dystopian-type future from occurring.

Visit the website of the U.S. Transhumanist Party at http://transhumanist-party.org/.

Become a member of the U.S. Transhumanist Party for free by filling out this form.

U.S. Transhumanist Party Discussion Panel on Life Extension – February 18, 2017

U.S. Transhumanist Party Discussion Panel on Life Extension – February 18, 2017

 

The New Renaissance Hat

Listen to and download the audio recording of this panel discussion at http://rationalargumentator.com/USTP_Life_Extension_Panel.mp3 (right-click to download).

For its second expert panel, the U.S. Transhumanist Party invited Bill Andrews, Aubrey de Grey, Ira Pastor, and Ilia Stambler to discuss life extension and the quest to reverse biological aging through science and technology.

This two-hour panel discussion, moderated by Chairman Gennady Stolyarov II, took place on Saturday, February 18, 2017, at 10 a.m. U.S. Pacific Time. In this interactive venue, many opportunities for fresh discourse arose on the possibility of achieving dramatically greater longevity within our lifetimes. The substance of the discussion begins at 4:25 in the recording.

Questions the panelists considered include the following:

(i) How would you characterize the current state of efforts to reverse senescence / lengthen human lifespans?
(ii) How does progress in the areas of research you have delved into compare to your expectations approximately 10 to 15 years ago?
(iii) What are the most significant challenges and obstacles that you perceive to exist in the way of achieving serious reversal of biological aging?
(iv) What key technologies and methods of delivering treatments to patients would need to be developed in order for longevity escape velocity to be affordably achieved society-wide?
(v) What political reforms and societal / attitudinal changes would you advocate to accelerate the arrival of effective treatments to reverse biological aging and lengthen lifespans?
(vi) Are you concerned about any current political trends and how they might affect the progress of research into combating biological aging?
(vii) What can laypersons who are sympathetic to your goals do in order to hasten their realization? How can the effort to defeat aging become as popular and widely supported as efforts to defeat cancer and ALS are today?
(viii) What lessons can the history of anti-aging research offer to those who seek to advocate and help achieve effective scientific breakthroughs in this area in the coming years and decades?

Become a member of the U.S. Transhumanist Party for free. Apply here.

References

Genetic stabilization of transthyretin, cerebrovascular disease, and life expectancy” – Paper by Louise S. Hornstrup, Ruth Frikke-Schmidt, Børge G. Nordestgaard and Anne Tybjærg-Hansen. Arteriosclerosis, Thrombosis, and Vascular Biology. 2013;33:1441-1447, Originally published May 15, 2013.

Recognizing Degenerative Aging as a Treatable Medical Condition: Methodology and Policy” – Paper by Ilia Stambler. Aging and Disease.

***

Panelists

Dr. Bill Andrews is the President and CEO of Sierra Sciences – http://www.sierrasci.com/. As a scientist, athlete, and executive, he continually pushes the envelope and challenges convention. In his 35-year biotech career, he has focused the last 23 years on finding ways to extend the human lifespan and healthspan through telomere maintenance. As one of the principal discoverers of both the RNA and protein components of human telomerase, Dr. Andrews was awarded 2nd place as “National Inventor of the Year” in 1997.

Dr. Aubrey de Grey is the biomedical gerontologist who researched the idea for and founded SENS Research Foundation – http://www.sens.org/. He received his BA in Computer Science and Ph.D. in Biology from the University of Cambridge in 1985 and 2000, respectively. Dr. de Grey is Editor-in-Chief of Rejuvenation Research, is a Fellow of both the Gerontological Society of America and the American Aging Association, and sits on the editorial and scientific advisory boards of numerous journals and organizations.

Ira Pastor has 30 years of experience across multiple sectors of the pharmaceutical industry, including pharmaceutical commercialization, biotech drug development, managed care, distribution, OTC, and retail. He is the CEO of BioQuark, Inc. – http://www.bioquark.com/ – and Executive Chairman of ReAnima Advanced Biosciences – https://reanima.tech/.

Dr. Ilia Stambler is a researcher at Bar Ilan University, Israel. His research focuses on the historical and social implications of aging and life-extension research. He is the author of A History of Life-extensionism in the Twentieth Century – www.longevityhistory.com. He is actively involved in advocacy for aging and longevity research – www.longevityforall.org.

MILE / U.S. Transhumanist Party Interview with Ira Pastor of Bioquark, Inc.

MILE / U.S. Transhumanist Party Interview with Ira Pastor of Bioquark, Inc.

The New Renaissance Hat

G. Stolyarov II

******************************

Gennady Stolyarov II, Chairman of the U.S. Transhumanist Party, was honored to interview entrepreneur and pharmaceutical industry veteran Ira Pastor for MILE – the Movement for Indefinite Life Extension – the U.S. Transhumanist Party, and the Nevada Transhumanist Party. The hour-long conversation delved into a variety of interrelated subject areas, including regeneration and repair mechanisms in animals, potential applications in humans, development of substances and treatments that could achieve victories against diseases and lead to longer lifespans, political and regulatory implications for the development of such substances, the importance of awareness of this research within the broader society, and even a “moonshot” project called ReAnima for repairing traumatic injury to organs and tissues that would otherwise cause irreversible death in accident victims.

This interview took place on Saturday, February 11, 2017, at 10 a.m. U.S. Pacific Time.

Read about Bioquark here.

Read about Mr. Pastor here.

Join the U.S. Transhumanist Party for free here.

Visit and like the MILE – Movement for Indefinite Life Extension – Facebook page here.

Congressman Lieu, Senator Markey Introduce the Restricting First Use of Nuclear Weapons Act of 2017 – Press Release by Congressman Ted Lieu & Senator Edward J. Markey

Congressman Lieu, Senator Markey Introduce the Restricting First Use of Nuclear Weapons Act of 2017 – Press Release by Congressman Ted Lieu & Senator Edward J. Markey

The New Renaissance Hat Congressman Ted Lieu (D-CA) & Senator Edward J. Markey (D-MA)
******************************

WashingtonToday, Congressman Ted W. Lieu (D | Los Angeles County) and Senator Edward J. Markey (D-Massachusetts) introduced the Restricting First Use of Nuclear Weapons Act of 2017.  This legislation would prohibit the President from launching a nuclear first strike without a declaration of war by Congress. The crucial issue of nuclear “first use” is more urgent than ever now that President Donald Trump has the power to launch a nuclear war at a moment’s notice.

Upon introduction of this legislation, Mr. Lieu issued the following statement:

“It is a frightening reality that the U.S. now has a Commander-in-Chief who has demonstrated ignorance of the nuclear triad, stated his desire to be ‘unpredictable’ with nuclear weapons, and as President-elect was making sweeping statements about U.S. nuclear policy over Twitter. Congress must act to preserve global stability by restricting the circumstances under which the U.S. would be the first nation to use a nuclear weapon. Our Founders created a system of checks and balances, and it is essential for that standard to be applied to the potentially civilization-ending threat of nuclear war. I am proud to introduce the Restricting First Use of Nuclear Weapons Act of 2017 with Sen. Markey to realign our nation’s nuclear weapons launch policy with the Constitution and work towards a safer world.”

Upon introduction of this legislation, Senator Markey issued the following statement:

“Nuclear war poses the gravest risk to human survival. Yet, President Trump has suggested that he would consider launching nuclear attacks against terrorists. Unfortunately, by maintaining the option of using nuclear weapons first in a conflict, U.S. policy provides him with that power. In a crisis with another nuclear-armed country, this policy drastically increases the risk of unintended nuclear escalation. Neither President Trump, nor any other president, should be allowed to use nuclear weapons except in response to a nuclear attack. By restricting the first use of nuclear weapons, this legislation enshrines that simple principle into law. I thank Rep. Lieu for his partnership on this common-sense bill during this critical time in our nation’s history.”

Support for the Restricting First Use of Nuclear Weapons Act of 2017:

William J. Perry, Former Secretary of Defense – “During my period as Secretary of Defense, I never confronted a situation, or could even imagine a situation, in which I would recommend that the President make a first strike with nuclear weapons—understanding that such an action, whatever the provocation, would likely bring about the end of civilization.  I believe that the legislation proposed by Congressman Lieu and Senator Markey recognizes that terrible reality.  Certainly a decision that momentous for all of civilization should have the kind of checks and balances on Executive powers called for by our Constitution.”

Tom Z. Collina, Policy Director of Ploughshares Fund – “President Trump now has the keys to the nuclear arsenal, the most deadly killing machine ever created. Within minutes, President Trump could unleash up to 1,000 nuclear weapons, each one many times more powerful than the Hiroshima bomb. Yet Congress has no voice in the most important decision the United States government can make. As it stands now, Congress has a larger role in deciding on the number of military bands than in preventing nuclear catastrophe.”

Derek Johnson, Executive Director of Global Zero – “One modern nuclear weapon is more destructive than all of the bombs detonated in World War II combined. Yet there is no check on a president’s ability to launch the thousands of nuclear weapons at his command. In the wake of the election, the American people are more concerned than ever about the terrible prospect of nuclear war — and what the next commander-in-chief will do with the proverbial ‘red button.’ That such devastating power is concentrated in one person is an affront to our democracy’s founding principles. The proposed legislation is an important first step to reining in this autocratic system and making the world safer from a nuclear catastrophe.”

Megan Amundson, Executive Director of Women’s Action for New Directions (WAND) – “Rep. Lieu and Sen. Markey have rightly called out the dangers of only one person having his or her finger on the nuclear button. The potential misuse of this power in the current global climate has only magnified this concern. It is time to make real progress toward lowering the risk that nuclear weapons are ever used again, and this legislation is a good start.”

Jeff Carter, Executive Director of Physicians for Social Responsibility – “Nuclear weapons pose an unacceptable risk to our national security. Even a “limited” use of nuclear weapons would cause catastrophic climate disruption around the world, including here in the United States. They are simply too profoundly dangerous for one person to be trusted with the power to introduce them into a conflict. Grounded in the fundamental constitutional provision that only Congress has the power to declare war, the Restricting First Use of Nuclear Weapons Act of 2017 is a wise and necessary step to lessen the chance these weapons will ever be used.”

Diane Randall, Executive Secretary of the Friends Committee on National Legislation (Quakers) – “Restricting first-use of nuclear weapons is an urgent priority. Congress should support the Markey-Lieu legislation.”

###

Fundraiser by Lifespan.io & CellAge: Targeting Senescent Cells With Synthetic Biology

Fundraiser by Lifespan.io & CellAge: Targeting Senescent Cells With Synthetic Biology

The New Renaissance HatCellAge
******************************

Editor’s Note: The Rational Argumentator and the U.S. Transhumanist Party support Lifespan.io and CellAge in their work towards groundbreaking scientific life-extension research. Finding a way to repair age-related damage to senescent cells would be a fundamental breakthrough for transhumanism, and we offer our best wishes and support for those striving towards these new technologies.

               ~ Gennady Stolyarov II, Editor-in-Chief, The Rational Argumentator, December 11, 2016

From Lifespan.io and CellAge:

Our society has never aged more rapidly – one of the most visible symptoms of the changing demographics is the exponential increase in the incidence of age-related diseases, including cancer, cardiovascular diseases and osteoarthritis. Not only does aging have a negative effect on the quality of life among the elderly but it also causes a significant financial strain on both private and public sectors. As the proportion of older people is increasing so is health care spending. According to a WHO analysis, the annual number of new cancer cases is projected to rise to 17 million by 2020, and reach 27 million by 2030. Similar trends are clearly visible in other age-related diseases such as cardiovascular disease. Few effective treatments addressing these challenges are currently available and most of them focus on a single disease rather than adopting a more holistic approach to aging.

Recently a new approach which has the potential of significantly alleviating these problems has been validated by a number of in vivo and in vitro studies. It has been demonstrated that senescent cells (cells which have ceased to replicate due to stress or replicative capacity exhaustion) are linked to many age-related diseases. Furthermore, removing senescent cells from mice has been recently shown to drastically increase mouse healthspan (a period of life free of serious diseases).

Here at CellAge we are working hard to help translate these findings into humans!

CellAge, together with a leading synthetic biology partner, Synpromics, are poised to develop a technology allowing for the identification and removal of harmful senescent cells. Our breakthrough technology will benefit both the scientific community and the general public.

In short, CellAge is going to develop synthetic promoters which are specific to senescent cells, as promoters that are currently being used to track senescent cells are simply not good enough to be used in therapies. The most prominently used p16 gene promoter has a number of limitations, for example. First, it is involved in cell cycle regulation, which poses a danger in targeting cells which are not diving but not senescent either, such as quiescent stem cells. Second, organism-wide administration of gene therapy might at present be too dangerous. This means senescent cells only in specific organs might need to be targeted and p16 promoter does not provide this level of specificity. Third, the p16 promoter is not active in all senescent cells. Thus, after therapies utilizing this promoter, a proportion of senescent cells would still remain. Moreover, the p16 promoter is relatively large (2.1kb), making it difficult to incorporate in present gene therapy vehicles. Lastly, to achieve the intended therapeutic effect the strength of p16 promoter to drive therapeutic effect might not be high enough.

CellAge will be constructing a synthetic promoter which has a potential to overcome all of the mentioned limitations. A number of gene therapy companies, including uniQure, AGTC and Avalanche Biotech have successfully targeted other types of cells using this technology. With your help, we will be able to use same technology to develop tools and therapies for accurate senescent cell targeting.